Rachel Moate

630 total citations · 2 hit papers
8 papers, 343 citations indexed

About

Rachel Moate is a scholar working on Immunology, Surgery and Emergency Medical Services. According to data from OpenAlex, Rachel Moate has authored 8 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Immunology, 4 papers in Surgery and 4 papers in Emergency Medical Services. Recurrent topics in Rachel Moate's work include IL-33, ST2, and ILC Pathways (6 papers), Pediatric health and respiratory diseases (4 papers) and Eosinophilic Esophagitis (4 papers). Rachel Moate is often cited by papers focused on IL-33, ST2, and ILC Pathways (6 papers), Pediatric health and respiratory diseases (4 papers) and Eosinophilic Esophagitis (4 papers). Rachel Moate collaborates with scholars based in United Kingdom, Sweden and Poland. Rachel Moate's co-authors include Andreas Wollenberg, Michael Howell, Jonathan I. Silverberg, Koustubh Ranade, René van der Merwe, Emma Guttman‐Yassky, G. Evoniuk, Emiliangelo Ratti, Jack G. Modell and Susan M. Learned and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, European Respiratory Journal and Journal of Psychopharmacology.

In The Last Decade

Rachel Moate

8 papers receiving 335 citations

Hit Papers

Treatment of atopic dermatitis with tralokinumab, an anti... 2018 2026 2020 2023 2018 2025 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
    2018 300 citations Andreas Wollenberg, Michael Howell et al. Journal of Allergy and Clinical Immunology profile →
  2. A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4
    2025 19 citations Dave Singh, Sarah Doffman et al. European Respiratory Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rachel Moate United Kingdom 3 259 212 118 76 52 8 343
Michael A. Zielinski United States 10 276 1.1× 237 1.1× 113 1.0× 54 0.7× 31 0.6× 16 377
Emily Boozalis United States 8 235 0.9× 85 0.4× 60 0.5× 99 1.3× 26 0.5× 17 261
Corrado Mirone Italy 9 69 0.3× 158 0.7× 131 1.1× 42 0.6× 32 0.6× 17 261
Dennis L. Spangler United States 10 62 0.2× 281 1.3× 168 1.4× 26 0.3× 86 1.7× 13 358
Niccolò Gori Italy 9 143 0.6× 75 0.4× 48 0.4× 43 0.6× 22 0.4× 24 188
Sonja Werner Sweden 8 62 0.2× 113 0.5× 102 0.9× 22 0.3× 12 0.2× 10 236
Marius Anton Ionescu France 5 137 0.5× 19 0.1× 16 0.1× 47 0.6× 100 1.9× 13 252
Schiela Jensen Denmark 3 95 0.4× 27 0.1× 44 0.4× 50 0.7× 16 0.3× 3 126
Anne‐Marie Calza Switzerland 6 116 0.4× 143 0.7× 53 0.4× 26 0.3× 1 0.0× 9 240
Ruby Pawankar Japan 8 96 0.4× 206 1.0× 176 1.5× 3 0.0× 5 0.1× 11 256

Countries citing papers authored by Rachel Moate

Since Specialization
Citations

This map shows the geographic impact of Rachel Moate's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Moate with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Moate more than expected).

Fields of papers citing papers by Rachel Moate

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Moate. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Moate. The network helps show where Rachel Moate may publish in the future.

Co-authorship network of co-authors of Rachel Moate

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Moate. A scholar is included among the top collaborators of Rachel Moate based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Moate. Rachel Moate is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Corren, Jonathan, Rachel Moate, Adam Williams, et al.. (2025). FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma. ERJ Open Research. 12(1). 183–2025. 1 indexed citations
2.
Singh, Dave, Sarah Doffman, Ulla Seppälä, et al.. (2025). A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4. European Respiratory Journal. 66(1). 2402231–2402231. 19 indexed citations breakdown →
3.
4.
Singh, Neeraj Pal, Sarah Doffman, Ulla Seppälä, et al.. (2024). S92 FRONTIER-4: a phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD. A68.1–A68. 1 indexed citations
5.
Doffman, Sarah, Ulla Seppälä, Rachel Moate, et al.. (2024). S91 Tozorakimab (anti-IL-33 mAb) reduces mucus plugging in COPD: an imaging sub-study in the FRONTIER-4 phase 2a COPD trial. A67–A68. 1 indexed citations
6.
Pandya, Hitesh, Sarah Doffman, Lars H. Nordenmark, et al.. (2024). Late Breaking Abstract - FRONTIER-4: a phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD. OA1964–OA1964. 1 indexed citations
7.
Wollenberg, Andreas, Michael Howell, Emma Guttman‐Yassky, et al.. (2018). Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb. Journal of Allergy and Clinical Immunology. 143(1). 135–141. 300 indexed citations breakdown →
8.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael A. Zielinski Breakdown of academic impact, for papers by Emily Boozalis Breakdown of academic impact, for papers by Corrado Mirone Breakdown of academic impact, for papers by Dennis L. Spangler Breakdown of academic impact, for papers by Niccolò Gori Breakdown of academic impact, for papers by Sonja Werner Breakdown of academic impact, for papers by Marius Anton Ionescu Breakdown of academic impact, for papers by Schiela Jensen Breakdown of academic impact, for papers by Anne‐Marie Calza Breakdown of academic impact, for papers by Ruby Pawankar
Rankless by CCL
2026